GLP-1 Medicines and the PBS in Australia: How Listing Works

Scope of this page

This is general information about how the Pharmaceutical Benefits Scheme works. FORM is a pathology testing service and does not prescribe, dispense, sell or arrange supply of any medicine, and nothing here is an availability claim or a recommendation.

PBS status is one of the most searched questions about GLP-1 medicines in Australia, and it is also one of the most poorly answered, because most pages state a status as of whenever they were written and then never update. A listing decision made in one PBAC cycle can be revisited in the next, and restrictions attached to a listing can be amended without the listing itself changing.

So rather than assert a status that decays, this page explains the mechanism — who decides, on what basis, and where the current answer lives — so you can check it yourself in about a minute and get the right answer on the day you look.

How a medicine gets listed on the PBS

A sponsor applies, the Pharmaceutical Benefits Advisory Committee assesses clinical effectiveness and cost-effectiveness for a specific indication and recommends for or against listing, and government then decides, with price negotiation following a positive recommendation.

The PBAC meets several times a year and publishes its outcomes shortly after each meeting, with fuller public summary documents released later. Those documents set out what was applied for, what the committee accepted or rejected, and why — usually turning on the incremental cost-effectiveness ratio, that is, the cost per unit of health benefit compared with existing treatment.

Two features of the process explain most of the confusion in this area. First, applications are indication-specific: a sponsor applies for subsidy for a defined clinical use, not for the product in general. Second, a recommendation is not a listing. After a positive recommendation, price must be negotiated and the listing must be given effect, which takes further time — so a medicine can be 'PBAC recommended' and still not subsidised at the pharmacy counter.

Rejections are also routine and not final. It is common for a medicine to be knocked back on cost-effectiveness grounds, resubmitted with a revised price or a narrower target population, and listed on a later attempt.

Why the same medicine can be subsidised for one person and not another

PBS listings carry restrictions — defined clinical criteria a patient must meet — so two people prescribed the same medicine can pay very different amounts depending on which criteria apply to them.

This is the most common source of surprise at the pharmacy counter. Someone reads that a medicine is 'on the PBS', is prescribed it for a different clinical reason than the listing covers, and is charged a private price. Both things are true at once: the medicine is listed, and their script is not subsidised.

Restrictions are published with the listing and are quite specific — they may require a particular diagnosis, a documented threshold on a test result, prior treatment with something else, or ongoing evidence of response. Some listings are 'authority required', meaning the prescriber must obtain approval before the subsidised script can be written.

Concession status is a second axis. Concession card holders pay a lower co-payment than general patients, and the PBS Safety Net reduces the amount further once annual household spending passes a threshold. Both figures are indexed each January.

• Check the restriction text, not just whether the medicine appears on the schedule.
• 'Authority required' means your prescriber must obtain approval before a subsidised script can be issued.
• Co-payment amounts differ between general and concessional patients and change annually.
• A private script for a listed medicine is still a private script — the listing does not help if you do not meet the criteria.

How to check the current position in about a minute

Search the medicine by name on pbs.gov.au for the current listing and restrictions, and check the PBAC outcomes pages for anything still in progress.

It is worth doing this yourself rather than relying on any secondary source, including this one. PBS listings change several times a year, and the cost of acting on stale information is a surprise at the counter.

• Go to pbs.gov.au and search the medicine's generic name (for example, the active ingredient rather than the brand) — that returns every listing including all indications.
• Read the restriction text attached to each listing. That is where the clinical criteria that determine your out-of-pocket cost live.
• Note the current general and concessional co-payment amounts, published on the same site and updated each January.
• For anything not yet listed, check the PBAC meeting outcomes pages — recommendations and rejections are published after each meeting, with public summary documents following.
• For supply questions rather than subsidy questions, use the TGA Medicine Shortage Reports Database.
• Then ask your pharmacist. For a private script, only they can quote what you will actually pay.

The bloods are worth doing either way

Subsidy status does not change what is happening in your metabolism, and the baseline markers — HbA1c, fasting glucose, lipids, liver function and thyroid — are worth documenting regardless of what any medicine costs.

People often put pathology on hold while they wait to find out whether a medicine will be subsidised. That is the wrong order. Bloods are inexpensive relative to everything else in this picture, they are the same tests whatever the subsidy outcome, and a baseline measured now is more valuable than the same test measured in six months, because it captures the 'before'.

There is also a practical point. If your HbA1c already sits in the diabetic range, or a liver enzyme is raised, or your thyroid function is abnormal, those findings change the clinical conversation — and in some cases change which PBS criteria are even relevant to you. Having them documented before the consultation is straightforwardly useful.

The full marker-by-marker breakdown, with Australian reference ranges and a conventional retest schedule, is on our GLP-1 monitoring panel page.

• No referral from your own GP is required. Privately requested pathology is arranged under a request from a registered medical practitioner working with our accredited lab partner.
• Collection is a walk-in blood draw at Laverty (Healius) pathology centres Australia-wide (NATA / ISO 15189 accredited).
• Results are returned in Australian SI units — mmol/mol and % for HbA1c, mmol/L for glucose and lipids, U/L for liver enzymes — with a written plain-English explanation.
• Your results are yours. Take them to your GP, an endocrinologist or whichever registered practitioner is managing your care; decisions about any medicine are theirs and yours, not ours.
• Australian ordering is currently pre-sale. Join the waitlist and we will email you when ordering opens.

Where to have these markers measured

The baseline metabolic set is carried by the standard FORM Australia panels, and each marker can also be selected individually in the builder.

• GLP-1 monitoring blood panel — Marker-by-marker detail, Australian reference ranges and a conventional retest rhythm.
• What GLP-1 treatment costs in Australia — The five cost categories, PBS versus private scripts, and where pathology sits.
• Australian blood test panels (Essential to Ultra) — Essential covers HbA1c, glucose, lipids, LFTs and thyroid; indicatively from A$299 in pre-sale.
• Build your own Australian panel — Pick only the metabolic markers you want, in a single blood draw.